Other News To Note
• Titan Pharmaceuticals Inc., of South San Francisco, said the FDA's Psychopharmacologic Drugs Advisory Committee is scheduled to review the firm's new drug application (NDA) for Probuphine for the maintenance treatment of adults with opioid dependence on March 21.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter